Overview

Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Status:
Unknown status

Trial end date:
2021-06-30

Target enrollment:

Participant gender:

Summary

This is a phase II pilot trial of Paclitaxel Protein Bound and Gemcitabine based chemotherapy and the addition of Paricalcitol upon attainment of stable or progressive disease in eligible patients with untreated metastatic pancreatic ductal adenocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Barts & The London NHS Trust

Treatments:

Albumin-Bound Paclitaxel
Cisplatin
Ergocalciferols
Gemcitabine
Paclitaxel